BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, $0.01 par value per share
Symbol
BCRX on Nasdaq
Shares outstanding
209,618,986
Price per share
$7.80
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
194,113,722
Total reported value
$1,473,202,263
% of total 13F portfolios
0%
Share change
-3,576,455
Value change
-$36,093,980
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
281
Price from insider filings
$7.65
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 8.4% $118,363,227 17,483,490 BlackRock, Inc. 31 Mar 2025
RA CAPITAL MANAGEMENT, L.P. 7.3% $116,143,592 15,302,186 RA Capital Management, L.P. 04 Nov 2025
Flynn James E 5.8% $103,071,430 12,169,000 Deerfield Mgmt, L.P. 12 Sep 2025
Avoro Capital Advisors LLC 4.2% $58,899,000 8,700,000 Avoro Capital Advisors LLC 31 Mar 2025
As of 30 Sep 2025, BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 281 institutional shareholders filing 13F forms. They hold 194,113,722 shares. of 209,618,986 outstanding shares (93%) .

Top 25 institutional shareholders own 68% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 10% 21,790,881 +6.1% 0% $165,392,786
BlackRock, Inc. 10% 21,245,876 -0.84% 0% $161,256,203
DEERFIELD MANAGEMENT COMPANY, L.P. 5.8% 12,169,000 +159% 1.4% $92,362,710
STATE STREET CORP 4.7% 9,807,438 +15% 0% $74,438,454
Kynam Capital Management, LP 4.5% 9,390,270 +11% 5.3% $71,272,149
UBS Group AG 2.8% 5,967,737 +6.3% 0.01% $45,295,124
ALKEON CAPITAL MANAGEMENT LLC 2.6% 5,464,021 -4.4% 0.19% $41,471,919
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 2.5% 5,225,986 +22% 0.03% $39,665,234
MORGAN STANLEY 2.5% 5,202,958 -2.4% 0% $39,490,449
GEODE CAPITAL MANAGEMENT, LLC 2.4% 5,052,307 -0.05% 0% $38,353,050
TWO SIGMA INVESTMENTS, LP 2.1% 4,419,629 +3.1% 0.05% $33,544,984
TWO SIGMA ADVISERS, LP 2% 4,240,712 +0.29% 0.06% $32,187,004
Hood River Capital Management LLC 1.7% 3,620,261 +191% 0.32% $27,477,781
Nuveen, LLC 1.7% 3,617,882 +2.4% 0.01% $27,459,724
Assenagon Asset Management S.A. 1.5% 3,092,592 -15% 0.03% $23,472,773
GOLDMAN SACHS GROUP INC 1.3% 2,711,806 -23% 0% $20,582,607
Fisher Asset Management, LLC 1.3% 2,632,696 -5.4% 0.01% $19,982,161
Qube Research & Technologies Ltd 1.1% 2,410,362 +1.6% 0.03% $18,294,648
GW&K Investment Management, LLC 1% 2,197,765 -16% 0.15% $16,681,000
RENAISSANCE TECHNOLOGIES LLC 1% 2,140,534 -15% 0.02% $16,246,653
BNP PARIBAS FINANCIAL MARKETS 1% 2,094,278 0% 0.01% $15,895,570
JUPITER ASSET MANAGEMENT LTD 0.98% 2,055,915 -1.1% 0.13% $15,604,395
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.95% 1,994,404 +1.2% 0% $15,137,526
BANK OF AMERICA CORP /DE/ 0.91% 1,902,819 -33% 0% $14,442,397
NORTHERN TRUST CORP 0.9% 1,892,043 -1.1% 0% $14,360,607

Institutional Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 777,006 $6,056,979 -$22,159,737 779.95% 6
2025 Q3 194,113,722 $1,473,202,263 -$36,093,980 759% 281
2025 Q2 197,129,798 $1,766,723,682 +$203,493,402 896% 292
2025 Q1 174,241,947 $1,307,295,119 +$63,398,498 750% 272
2024 Q4 167,634,434 $1,260,963,178 -$35,871,411 752% 255
2024 Q3 172,461,082 $1,310,699,249 -$17,336,963 760% 256
2024 Q2 174,329,025 $1,077,168,420 -$19,756,856 618% 238
2024 Q1 178,794,692 $908,282,297 +$13,485,290 508% 235
2023 Q4 995,388 $5,966,374 -$2,259,291 599% 3
2023 Q3 174,862,085 $1,237,990,036 +$20,589,255 708% 227
2023 Q2 173,206,131 $1,219,704,380 +$8,684,728 704% 231
2023 Q1 170,642,621 $1,423,147,428 +$92,086,582 834% 236
2022 Q4 156,295,197 $1,794,049,107 +$88,196,374 1,148% 222
2022 Q3 146,813,145 $1,849,838,441 -$41,569,875 1,260% 213
2022 Q2 146,233,112 $1,547,163,393 +$165,531,197 1,058% 201
2022 Q1 126,959,618 $2,062,986,346 +$165,963,093 1,626% 214
2021 Q4 117,818,574 $1,621,609,826 +$192,813,352 1,385% 195
2021 Q3 103,285,552 $1,484,285,647 -$24,064,477 1,437% 193
2021 Q2 104,610,942 $1,653,827,922 +$17,817,538 1,580.99% 190
2021 Q1 104,349,292 $1,061,228,812 -$140,145,824 1,017% 182
2020 Q4 120,522,116 $897,817,805 -$44,459,095 745% 171
2020 Q3 127,492,897 $438,150,012 -$23,520,218 343.5% 148
2020 Q2 130,802,567 $623,563,637 +$86,629,537 476.49% 155
2020 Q1 122,545,605 $245,076,906 -$37,554,838 200% 127
2019 Q4 136,461,895 $470,563,973 +$128,774,005 345% 126
2019 Q3 97,207,334 $278,518,178 -$6,766,703 286.5% 105
2019 Q2 99,769,274 $378,061,222 -$88,271,855 378.99% 109
2019 Q1 100,836,648 $820,777,210 -$625,456 814% 126
2018 Q4 100,991,756 $815,022,643 +$8,360,187 807% 115
2018 Q3 100,110,755 $763,814,804 +$74,212,788 763% 108
2018 Q2 87,369,622 $500,633,833 -$8,950,141 573.01% 96
2018 Q1 89,040,228 $424,731,405 -$6,559,729 477% 97
2017 Q4 90,256,578 $443,198,769 +$31,862,065 491% 110
2017 Q3 83,551,707 $436,150,628 +$74,612,419 524% 115
2017 Q2 68,664,954 $381,777,979 +$5,091,371 556% 109
2017 Q1 67,622,424 $566,335,791 +$138,336,571 839.99% 113
2016 Q4 58,390,925 $369,592,679 +$11,847,838 633% 107
2016 Q3 56,535,325 $249,323,126 +$24,615,920 441% 97
2016 Q2 51,199,104 $145,407,142 -$10,363,828 284% 89
2016 Q1 53,854,466 $152,388,490 -$59,466,616 282.99% 98
2015 Q4 63,010,560 $650,239,667 -$41,772,947 1,031.98% 116
2015 Q3 63,700,390 $726,067,332 +$33,949,200 1,140% 121
2015 Q2 62,218,189 $928,841,410 +$39,236,791 1,492.97% 119
2015 Q1 58,019,025 $523,923,031 +$37,779,102 903% 95
2014 Q4 53,661,254 $652,337,154 +$25,558,717 1,216% 87
2014 Q3 56,671,269 $554,269,573 -$6,975,870 978% 100
2014 Q2 49,824,717 $635,343,598 +$146,396,546 1,275% 98
2014 Q1 43,477,549 $460,381,679 +$93,247,043 1,057.99% 85